contains 57 functional P450 genes arranged into 18 families and 42 subfamilies (Guengerich, 2005) . Members of the CYP1, CYP2, CYP3, and, to a lesser extent, CYP4 families metabolize exogenous substrates (e.g., drugs, herbs, and environmental pollutants) with little contribution from other P450 families (Nebert and Russell, 2002) . The CYP3A subfamily has received the most attention of all drug-metabolizing enzymes due to its abundant expression in major organs of drug elimination (i.e., liver and intestine) (Shimada et al., 1994; Paine et al., 2006) , its ability to metabolize a wide range of structurally diverse substrates, and its dominant role in drug metabolism (Wilkinson, 2005) . Within the CYP3A subfamily, CYP3A4 is the most abundantly expressed form in the liver, whereas CYP3A5 expression at the protein level is only about 10.6%
of that of CYP3A4 (Wang et al., 2008) . CYP3A7 is considered a fetal-specific P450 enzyme (Leeder et al., 2005) , and CYP3A43 has extremely low expression in the liver and contributes little to drug metabolism (Domanski et al., 2001; Westlind et al., 2001 ).
The CYP4F subfamily of enzymes was discovered during efforts to identify enzymes involved in the ω-hydroxylation of eicosanoids (e.g., leukotriene B 4 [LTB4], prostaglandins and arachidonic acid) (Kalsotra and Strobel, 2006; Hsu et al., 2007) . This subfamily is comprised of five members, CYPs 4F2, 4F3, 4F8, 4F11 and 4F12. Of these, the CYP4F3 gene produces two tissue-specific splice variants, CYP4F3A (myeloid form) and CYP4F3B (liver form); however, transcripts of both are present in other tissues (Christmas et al., 2001) . CYP4F2 is the principal hepatic ω-hydroxylase of the proinflammatory agent LTB4 and arachidonic acid D M D # 5 8 0 4 0 5 (Powell et al., 1998) , resulting in deactivation of LTB4 and formation of the potent vasoconstrictor 20-HETE, respectively. In addition, CYP4F2 catalyzes the ω-hydroxylation of tocopherol (vitamin E) and phylloquinone (vitamin K 1 ) phytyl side chains, suggesting roles in the regulation of vitamin E status and synthesis of clotting factors in the liver (Sontag and Parker, 2002; McDonald et al., 2009 ). Both CYP4F3A and CYP4F3B catalyze the ω-hydroxylation of LTB4 and arachidonic acid; however, CYP4F3A has 30-fold greater affinity (K m ) for LTB4 and conversely, 8.4-fold lower affinity for arachidonic acid than CYP4F3B (Christmas et al., 2001 ). Due to the involvement of CYP4F enzymes in the inactivation of LTB4, it has been suggested that these enzymes play an important role in the resolution of inflammation (Hardwick, 2008; Sehgal et al., 2011) .
Besides endogenous substrates, CYP4F enzymes have been implicated in the metabolism of xenobiotics. Notably, CYP4F11 metabolizes erythromycin and ethylmorphine (Kalsotra et al., 2004) , and CYP4F12 metabolizes ebastine (Hashizume et al., 2002) . CYP4F2 and/or CYP4F3B are the major hepatic enzymes that catalyze the ω-hydroxylation of fingolimod (FTY720), an oral drug for relapsing multiple sclerosis (Jin et al., 2011) , and O-demethylation of the antitrypanosomal methamidoxime prodrugs, pafuramidine (DB289), DB844 and DB868 (Wang et al., 2006; Generaux et al., 2013; Ju et al., 2014) . In addition, a CYP4F2 genetic polymorphism has been shown to significantly affect the required maintenance dose of warfarin (Caldwell et al., 2008) . Taken together, CYP4F enzymes, particularly hepatic CYP4F2 and CYP4F3B, play an important role in drug metabolism, as well as endogenous lipid metabolism. Therefore, it is important to quantify these enzymes at the protein level in order to define their inter-individual variability in hepatic expression and function. (Wang et al., 2008) . Similar methodology also has been applied for the quantification of drug transporters and UDP-glucuronosyltransferases (UGTs) (Fallon et al., 2008; Kamiie et al., 2008; Li et al., 2008 digestions were performed as previously described (Wang et al., 2008) with slight modifications.
Briefly, protein samples (10 -30 µg) were reduced in buffer (90 µL) containing 50 mM ammonium bicarbonate (pH 8) and 4 mM DTT, followed by heating at 60°C for 60 min to further denature the proteins. After cooling to room temperature, the samples were alkylated with IAA (10 mM final concentration) for 20 min in the dark and then subjected to digestion with 1 µg trypsin at 37°C for 4 h. A half-volume of ice-cold acetonitrile, containing
an Agilent HPLC column (Zorbax Poroshell 300SB-C18, 2.1×75 mm, 5 μ m) as described previously (Wang et al., 2008) .
Preparation of Calibration Standards. Calibration standards were prepared by subjecting various concentrations of recombinant P450s (0.01 -10 pmol) to digestion in parallel with
HLMs. The proteotypic peptides resulting from protein trypsinolysis were used to generate calibration curves. Quantification was performed using the area ratio of proteotypic peptide peak to the corresponding isotope-labeled peptide peak (present at a constant level due to its use as an IS) with 1/x 2 weighting. The accuracy and the coefficient of variation (CV) of the methods were determined by measuring triplicate preparations of the calibration standards.
Marker Activities and Western Blot Analysis. Testosterone 6β-hydroxylation and midazolam 1'-hydroxylation activities for the two HLM panels were provided by XenoTech. Midazolam 1'-hydroxylation activity also was evaluated in-house as described previously (Wang et al., 2007) to confirm the manufacturer-provided values and ensure sample integrity following delivery and storage. DB289 M1 formation, a proposed marker for CYP4F activity in HLMs, was measured as described previously (Wang et al., 2006) . Briefly, following pre-incubation at 37°C for 5 min, Final CYP4F2 and CYP4F3B protein content were calculated as the average values determined using two proteotypic peptides, "_pep1" and "_pep2". Total CYP4F content was determined as the sum of CYP4F2 and CYP4F3B protein content for each individual donor HLM. The contribution of CYP4F to the human liver P450 "pie" was determined by assuming the total This article has not been copyedited and formatted. The final version may differ from this version. μ g of HLM, was 1.7 pmol/mg HLM for CYP4F2 and CYP4F3B, and 0.3 pmol/mg HLM for CYP3A4, CYP3A5 and total CYP3A. For CYP4F2, the accuracy and the average CV of the analytical method were 83.0 -108% and 13% using 4F2_pep1, and 86.4 -108% and 20% using 4F2_pep2, respectively. For CYP4F3B, the accuracy and the average CV of the analytical method were 87.3 -113% and 19% using 4F3B_pep1, and 83.7 -118% and 9% using 4F3B_pep2, respectively. In addition, the accuracy and the average CV of the analytical method for CYP3A, CYP3A4 and CYP3A5 were 77 -124% and 19% using 3A_pep1, 85.3 -108% and 18% using 3A4_pep1, and 81.3 -114% and 22% using 3A5_pep1, respectively, similar to previously reported values (Wang et al., 2008) .
Absolute Quantification of CYP4F2 and CYP4F3B in HLMs and Correlation to
Immunoquantification. The absolute protein expression levels of CYP4F2 and CYP4F3B were determined in two individual donor HLM panels. Two unique proteotypic peptides, designated "_pep1" and "_pep2", were identified for each isoform and used for the quantification of protein Figure 3A) . The final average (range and 95% CI) CYP4F3B protein content was 10.4 (6.7 -13.9 and 9.4 -11.4) and 12.8 (6.4 -20.9 and 10 -15.8) pmol/mg HLM protein, respectively ( Figure 3B ). Overall, the average (range and 95% CI)
CYP4F2 and CYP4F3B protein contents in both HLM panels (n=31) were 14.3 (1.3 -27.1 and 12.1 -16.3) and 11.3 (6.4 -20.9 and 10.1 -12.5) pmol/mg HLM protein, respectively.
To validate the MS-based quantification of CYP4F2 and CYP4F3B, these results were compared to the immunoquantification of CYP4F enzymes in the same HLM panels. The polyclonal antibody against CYP4F2 utilized in this study was shown previously to cross-react with CYP4F3B in a similar manner, but not with CYPs 3A4, 3A5 or 4A11 (Wang et al., 2007) .
Hence, immunoquantification results represent the sum of CYP4F2 and CYP4F3B expression. reported previously (Wang et al., 2008) ; here, results from the first HLM panel are presented ( Figure 5 ). Total CYP3A was quantified using the proteotypic peptide 3A_pep1 (Table 1) and 0 -8.3) pmol/mg HLM protein (Wang et al., 2008) . Average (range and 95% CI) protein content for CYP3A, CYP3A4 and CYP3A5 in the third HLM panel were reported previously to be 32 (6 -85 and 22 -42), 30 (9.5 -70 and 22 -39) and 4.7 (0.2 -34 and 1.5 -8.0) pmol/mg HLM protein (Wang et al., 2008) . Overall, CYP3A5 was expressed at much lower levels than CYP3A4 (~10% of CYP3A4), and exhibited a 170-fold inter-individual variability within the 52 individual donor HLMs studied. CYP3A4 also exhibited significant inter-individual variability, 36-fold overall or 11-fold if H079 was excluded. Total CYP3A showed 43-fold inter-individual variability, unless H079 was excluded, at which it was only 21-fold. When total CYP3A (based on 3A_pep1) was plotted against the sum of CYP3A4 and CYP3A5 (based on 3A4_pep1 and 3A5_pep1, respectively) for the first HLM panel, a strong correlation (r 2 = 0.996) and near-unity slope (slope = 1.27) were observed (data not shown), similar to those previously reported for the second and third HLM panels (Wang et al., 2008) . These results confirm concordance of the LCThis article has not been copyedited and formatted. The final version may differ from this version. P450s, notably CYPs 1A2, 2J2 and 3A4, were implicated previously in catalyzing M1 formation, though these were shown to have a minor contribution to overall M1 formation in pooled HLMs (Wang et al., 2006) . However, it is possible that inter-individual variability in P450 expression could result in some individual donor HLMs having more-than-average contributions from these non-CYP4F enzymes, thus complicating the correlation analyses described earlier.
To assess this possibility, we determined residual M1 formation activities upon inhibition of non-CYP4F
enzymes by P450-selective chemical inhibitors. Due to the low expression of CYP2J2 in HLMs (< 1.7 pmol/mg HLM proteins; unpublished data) (Girault et al., 2005) , no experiments were performed with CYP2J2 inhibitors. Fluvoxamine was chosen as a CYP1A2 inhibitor (Pastrakuljic et al., 1997) ; azamulin (Stresser et al., 2004) and dihydroxybergamottin (DHB) (Araki et al., 2012) as CYP3A inhibitors. We chose not to use ketoconazole as a CYP3A
inhibitor because it is known to inhibit CYP4F2-mediated reactions (e.g., DB289 M1 formation (Wang et al., 2006) and fingolimod ω -hydroxylation (Jin et al., 2011) ). In addition, we chose HET0016, an arachidonic acid P450-mediated metabolism inhibitor (Wang et al., 2007) , as a CYP4F inhibitor to assess the contribution of CYP4F enzymes to M1 formation in our panel of individual donor HLMs.
Prior to incubation with HLMs, the inhibitors were incubated with recombinant P450s and DB289 to evaluate their specificity with respect to M1 formation ( Figure 7A ). HET0016 (0.1 µM) was a potent inhibitor of CYP4F2 (92% inhibition) and CYP4F3B (99% inhibition), and to a lesser extent, CYP2J2 (71% inhibition). HET0016 marginally inhibited CYP1A2 (27% This article has not been copyedited and formatted. The final version may differ from this version. inhibition) and CYP3A4 (4% inhibition). Fluvoxamine (3 µM) was a potent inhibitor of CYP1A2 (98% inhibition), but marginally inhibited CYP3A4 (21% inhibition), CYP4F2 (12% inhibition), CYP4F3B (24% inhibition) and CYP2J2 (27% inhibition). Azamulin (3 µM) was a moderate inhibitor of both CYP3A4 (54% inhibition) and CYP2J2 (46% inhibition), and did not significantly inhibit CYP1A2 (no inhibition), CYP4F2 (21% inhibition) or CYP4F3B (20% inhibition). Unexpectedly, DHB (30 µM) was a potent inhibitor of CYP4F2 (95% inhibition), CYP1A2 (84% inhibition) and CYP2J2 (93% inhibition), and to a lesser extent, CYP4F3B (59% inhibition). Interestingly, DHB, which potently inhibited CYP3A4-mediated midazolam 1'-hydroxylation (93% inhibition; data not shown), did not inhibit CYP3A4-mediated DB289 M1 formation ( Figure 7A ). The ability to quantitate absolute protein content without the need for antibody production is highly attractive. Costs and time associated with developing antibodies specific for the accurate quantitation of homologous proteins is significant. In addition, antibody-based assays are not always amenable to high-throughput screening, which is desired from a drug development perspective. Therefore, the use of LC-MS/MS techniques for quantitative proteomics has received significant attention in recent years.
The currently described LC-MS/MS method was applied to a panel of 20 individual donor HLMs in order to evaluate absolute protein content and inter-individual variability of specific enzymes. A second panel of 11 individual donor HLMs that were characterized previously for CYP4F content using similar methodology also was included. Overall, CYP4F2
exhibited considerable inter-individual variability (21-fold) in the two HLM panels ( Figure 3A) .
Conversely, CYP4F3B displayed much less inter-individual variability (3.3-fold) ( Figure 3B ).
However, it should be noted that two HLM samples contained very low levels of CYP4F2 variability observed in the two HLM panels was about 43-fold ( Figure 5A ). It has been estimated that the constitutive variability in CYP3A enzymes is about 5-fold, but that this variability can be increased as much as 400-fold due to various factors, including co-administration of inhibitors or inducers, environmental factors, and various disease states (Wilkinson, 2005) .
The results presented herein suggest that the CYP4F family of enzymes represent a significant portion of the overall human liver P450 "pie". It was shown previously that CYP1A2, CYP2A6, CYP2B6, CYP2C, CYP2D6, CYP2E1 and CYP3A accounted for approximately 70% of the total human liver P450 content; the remaining 30% consisted of then unknown enzymes (Shimada et al., 1994) . Based on the results of this work, it is proposed that a significant portion (~15%) of the previously unknown enzyme content is accounted for by CYP4F enzymes, making them the third largest piece of the human liver P450 "pie" (Figure 8 ). This supports the hypothesis that CYP4F enzymes may play an important role in the metabolism of endogenous and exogenous substances in the human body.
Compared to the previously reported average CYP4F2 content in the HLM (Edson et al., 2013) , an identical result (14.3 pmol/mg HLM protein) was obtained in our study consisting of 31 individual donor HLMs. In addition, Edson et al. (Edson et al., 2013) reported that another member of CYP4F subfamily, CYP4F11, was also expressed in the human liver at a level of 8.4
pmol/mg HLM protein. This would suggest that CYP4F enzymes make up an even larger portion of the P450 "pie" than that reported herein, approximately 18-21% when CYP4F11 is also taken into consideration. It is not known whether DB289 is a substrate of CYP4F11. If true, it may This article has not been copyedited and formatted. The final version may differ from this version. have contributed to the lack of correlation between DB289 M1 formation and CYP4F protein content (sum of CYP4F2 and CYP4F3B) observed in this study ( Figure 6A ).
In addition to the liver, CYP4F enzymes have been identified as the major enteric enzymes responsible for DB289 M1 formation, indicating there is significant expression of these enzymes in the intestine (Wang et al., 2007) . However, no quantitative analysis has yet been performed to indicate how CYP4F content in the intestine contributes to the overall enteric P450
"pie". Further study is required to understand the significance of CYP4F expression in the intestine and how it may affect processes such as the first-pass metabolism of therapeutic agents or the maintenance of intestinal homeostasis through the metabolism of various endogenous substances.
The correlation of protein content and enzyme activity was evaluated for CYP4F and CYP3A enzymes. No correlation was observed between CYP4F protein content (or RAFadjusted CYP4F protein content) and DB289 M1 formation ( Figure 6A ), though it has been shown previously that CYP4F2 and CYP4F3B are the major hepatic enzymes responsible for this biotransformation (Wang et al., 2006) . Good coherence between LC-MS/MS protein content and immunoquantified values suggest that the lack of correlation with activity is unlikely due to incorrectly measured protein content. The chemical inhibition assays ( Figure 7B ) suggest that while CYP4F enzymes are responsible for a major portion of the observed DB289 M1 formation, additional metabolic pathways likely exist. Our previous work (Wang et al., 2006) has implicated CYPs 1A2, 2J2 and 3A4 as enzymes capable of catalyzing DB289 M1 formation, though these were shown to have a minor contribution in the overall M1 formation in pooled HLMs.
Nonetheless, it is possible that inter-individual variability in P450 expression could result in some individual donor HLMs having more-than-average contributions from these non-CYP4F enzymes, thus complicating the correlation analyses. To assess this possibility, residual activities of DB289 M1 formation were determined upon inhibition of non-CYP4F enzymes using P450-selective chemical inhibitors ( Figure 7C ). No correlation was observed between CYP4F protein content and the residual M1 formation rates. The lack of an improved correlation following chemical inhibition suggests that DB289 M1 formation is not a good marker activity for CYP4F2
and/or CYP4F3B in HLMs. However, due to the ease of this assay compared to other CYP4F lipid substrates (e.g., LTB4 and arachidonic acid), DB289 M1 formation still may be a useful functional activity assay for CYP4F2 or CYP4F3B when other contributing pathways are absent (e.g., recombinant enzymes and drug induction studies with complementary assays).
Strong correlations (r 2 ≥ 0.78) were observed for all CYP3A marker activities. This was not unexpected as CYP3A continues to be one of the most studied P450 subfamilies. As such, the metabolic pathways that are used to evaluate CYP3A enzymatic activity have been well characterized over decades of use. However, surprising results were obtained with respect to the inhibition of CYP3A4-mediated DB289 M1 formation by DHB. This compound has been considered to be a substrate-independent reversible and mechanism-based inhibitor of CYP3A (Paine et al., 2004 ), yet negligible inhibition of CYP3A4-mediated DB289 M1 formation was observed ( Figure 7A ). This underlines previous observations that inhibition of CYP3A4 catalytic activity is substrate-dependent (Stresser et al., 2000; Wang et al., 2000) and that DHB may not be substrate-independent as previously thought.
This article has not been copyedited and formatted. The final version may differ from this version. Another potential explanation for the lack of correlation between CYP4F protein content and the observed DB289 M1 formation rate may be altered catalytic activity due to CYP4F2 genetic polymorphisms. Two functional variants, W12G and V433M, were identified recently (Bardowell et al., 2010) . The V433M variant has been implicated in inter-individual variability associated with warfarin maintenance dose due to effects on vitamin K 1 metabolism (McDonald et al., 2009 ). Both variants exhibit altered vitamin E metabolism (Bardowell et al., 2010) .
Interestingly, the variants have been linked to both increased and decreased catalytic activity, with the effects appearing to be substrate dependent. In addition, it has been suggested that the effects on metabolic activity may occur through reduction of the amount of enzyme present, either by inhibiting translation or inducing degradation, or by attenuation of catalytic activity itself. However, it was not possible to examine the effect of genetic polymorphisms on CYP4F expression and catalytic activity in this study due to the lack of genetic polymorphism information for the HLM panels. Correlation analyses of CYP4F2 (A) and CYP4F3B (B) protein concentrations, determined using peptides designated "_pep1" and "_pep2", were performed to evaluate the coherence of the proteotypic peptides. The inset figure depicts the percent contributions of individual P450 enzymes based on the immunoquantification performed by Shimada et al. (1994) . The larger figure shows the revised P450 "pie" with CYP4F contributing to 15% of the total hepatic P450s.
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